Month: September 2021

Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 AstraZeneca intends to advance and accelerate the Phase 3 development of CAEL-101 for light chain (AL) amyloidosis HSR waiting period has expired for the acquisition of Caelum NEW YORK and BORDENTOWN, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, and a company it founded, Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today announced that AstraZeneca’s...

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is pleased to report that William (Bill) Shaver, P. Eng., has been appointed to the Board of Directors effective immediately.  Mr. Shaver is a seasoned mining executive with over 50 years of management and executive experience in all facets of mine design, construction, and operations. In 1980, he was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as the Ernst and Young Entrepreneur of the Year for his devotion to bringing innovation to the mining industry. Most recently, he served as Chief Operating Officer of INV Metals before its sale to Dundee Precious Metals. He completed the Technician Program at the Haileybury School of Mines and is a Professional...

OTTAWA, Sept. 29, 2021 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) today announced that management will participate in A.G.P.’s Virtual Fall Consumer Cannabis Conference. Sebastien St-Louis, Chief Executive Officer, will participate on a panel on the Canadian market & the role of innovation to drive further growth on October 5th, 2021 at 10:00 a.m. ET. About HEXO HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, Redecan, UP Cannabis, Namaste Original Stash, 48North, Trail Mix, Bake Sale, REUP and Latitude brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss...

FDA Sets PDUFA Target Action Date of May 29, 2022 for the New Drug Application and July 29, 2022 for the Biologics License Application On Track for MAA Submission in the Fourth Quarter of this Year PHILADELPHIA, Sept. 29, 2021 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for AT-GAA, the Company’s investigational two-component therapy for the treatment of Pompe disease. Pompe disease is a rare genetic disease that causes premature death and has a debilitating effect on people’s lives. The U.S. represents the single largest geography for Amicus to positively impact the lives of people with Pompe disease. The FDA has set a...

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that management will participate in a fireside chat during the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Wednesday, Oct. 6, 2021 at 1:30 p.m. ET. The live webcast will be available in the investor section of the company’s website at investors.adagiotx.com. The webcast will be archived for 60 days following the presentation. About Adagio TherapeuticsAdagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious...

TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Kirkland Lake Gold Ltd. (“Kirkland Lake Gold” or the “Company”) (TSX:KL) (NYSE:KL) (ASX:KLA) today reported that, following the announcement of a merger of equals agreement with Agnico Eagle Mines Limited, the Company has suspended its automatic share purchase plan (“ASPP”) effective today, September 28, 2021. The ASPP was launched on June 21, 2021 in connection with the Company’s normal course issuer bid (“NCIB”) to allow for share purchases that would not be subject to black-out periods or other restrictions. The current NCIB remains in effect on the same terms and conditions as previously disclosed. Under the current NCIB, the Company can purchase up to 26,694,051 common shares until the expiry of the NCIB on June 8, 2022. A total of 3,392,100 common shares have been repurchased to...